What Is Dexcom’s Stelo and Why Is the FDA Expanding Its Use?
The U.S. Food and Drug Administration (FDA) has expanded the approved age range for Dexcom’s Stelo continuous glucose monitoring (CGM) system to include children as young as 2 years old, according to a December 2023 update. This decision, reported by Medscape Medical News, marks a significant shift in the device’s accessibility for younger patients with diabetes.
How Does the Stelo Device Work and What Is Its Purpose?
Stelo is a wireless CGM system designed to track glucose levels in real time, providing data to patients and caregivers through a mobile app. It is intended for individuals with type 1 or type 2 diabetes who require frequent glucose monitoring. The device uses a small sensor placed on the arm, which transmits readings to a receiver or smartphone.
What Did the FDA’s Decision Include and Why Was It Made?
The FDA’s revised approval, first announced by Dexcom in a press release, extends the device’s use to children aged 2 to 17 years. Previously, Stelo was approved for patients 12 and older. The agency cited clinical trial data demonstrating the device’s safety and accuracy in younger age groups, as well as feedback from pediatric endocrinologists.
What Are the Implications for Patients and Caregivers?
This expansion could improve diabetes management for younger patients, allowing for earlier intervention and better glucose control. According to the American Diabetes Association, early use of CGMs in children has been linked to reduced hypoglycemic events and improved long-term outcomes. However, caregivers are advised to consult healthcare providers to determine the device’s suitability for individual cases.
What Are the Next Steps for Dexcom and the Medical Community?
Dexcom has stated it will work with insurers to ensure coverage for the expanded age group, though some plans may require prior authorization. The Endocrine Society has called for further studies on long-term usage in toddlers, emphasizing the need for ongoing monitoring.
Why Does This Matter for Diabetes Care?
The FDA’s decision aligns with broader efforts to personalize diabetes treatment. In 2022, the agency approved similar CGM devices for younger children, reflecting a trend toward earlier integration of digital health tools. For families, this could mean more proactive management of blood sugar levels, potentially reducing complications.
What Should Patients Know About Using Stelo?
Patients should be aware that Stelo requires regular calibration with fingerstick tests and that sensor accuracy may vary. Dexcom’s website provides detailed instructions for use, and the company offers customer support for troubleshooting.
How Does This Compare to Other CGM Devices?
Stelo joins other CGM systems, such as Abbott’s FreeStyle Libre and Medtronic’s Guardian, in expanding pediatric use. However, Stelo’s unique feature is its smaller sensor size and longer wear time (up to 14 days), which may appeal to younger users.
What Are the Costs and Insurance Coverage Details?
The cost of Stelo varies by region and insurance plan. As of 2023, many commercial insurers cover CGMs for children with diabetes, though out-of-pocket expenses may apply. Dexcom’s website includes a coverage tool to help patients estimate costs.
What Are the Potential Risks or Limitations?
While the FDA approved Stelo for younger patients, it noted that the device is not recommended for use during pregnancy or in individuals with certain skin conditions. Users should also be cautious of sensor placement, as improper application can affect readings.
What Is the Broader Impact on Diabetes Management?
The expanded approval reflects growing confidence in CGM technology as a standard of care. A 2023 study in *JAMA Pediatrics* found that CGM use in children under 6 reduced severe hypoglycemia by 40%. As adoption increases, experts anticipate further innovations in pediatric diabetes tools.